Drug Safety

, Volume 39, Issue 5, pp 455–464 | Cite as

Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from VigiBase®

  • Jitka Pokladnikova
  • Ronald H. B. Meyboom
  • Ricarda Meincke
  • David Niedrig
  • Stefan Russmann
Original Research Article



Herbal medicines are used worldwide and with an increasing popularity in Western countries. Although often perceived as ‘naturally safe’, herbals may cause severe adverse drug reactions (ADRs), with immediate allergic reactions being particularly life threatening.


The aim of this study was to analyse immediate allergy-like ADRs to herbals documented in VigiBase®, the WHO international pharmacovigilance database.


The documentation of all suspected ADRs in association with herbal exposure reported to VigiBase® from 1969 to August 2014 was retrieved. Among all reports in which WHO-ART reaction terms were indicative of acute allergic reactions, those classified as ‘suspect’ with a documented causality assessment and latency time of ≤1 day were selected. For the most frequent specific herbal–ADR combinations, the information component (IC) as a measure of disproportionality based on Bayesian statistics was calculated.


We identified 757 reports out of 1039 ADRs. Products with mixed herbals (36.0 %) as well as those administered orally (63.2 %) were predominant. The most frequent reactions were urticaria and rash (49.2 %). Anaphylactic reactions accounted for 9.5 %. Disproportionally frequent reporting of mouth edema (IC = 1.81) and anaphylactic reactions (IC = 1.24) to Phleum pretense were noted.


Our findings indicate that herbal medicines for oral use carry a risk of causing immediate allergy-like ADRs. Studies using the Vigibase® database can identify specific combinations of particular herbs and adverse reactions. Healthcare professionals and patients should be aware of these risks and report any serious adverse experiences.


  1. 1.
    Eardley S, Bishop FL, Prescott P, Cardini F, Brinkhaus B, Santos-Rey K, et al. A systematic literature review of complementary and alternative medicine prevalence in EU. Forsch Komplement. 2012;19:18–28.CrossRefGoogle Scholar
  2. 2.
    MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust. 2006;184(1):27–31.PubMedGoogle Scholar
  3. 3.
    Wu CH, Wang CC, Tsai MT, Huang WT, Kennedy J. Trend and pattern of herb and supplement use in the United States: results from the 2002, 2007, and 2012 national health interview surveys. Evid Based Complement Altern Med eCAM. 2014;2014:872320.Google Scholar
  4. 4.
    Nissen N, Schunder-Tatzber S, Weidenhammer W, Johannessen H. What attitudes and needs do citizens in Europe have in relation to complementary and alternative medicine? Forsch Komplement. 2012;19:9–17.CrossRefGoogle Scholar
  5. 5.
    Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Braz J Med Biol Res. 2000;33(2):179–89.CrossRefPubMedGoogle Scholar
  6. 6.
    Wiesener S, Falkenberg T, Hegyi G, Hok J, Roberti di Sarsina P, Fonnebo V. Legal status and regulation of complementary and alternative medicine in Europe. Forsch Komplement. 2012;19:29–36.Google Scholar
  7. 7.
    Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews. Eur J Clin Pharmacol. 2013;69(3):295–307.CrossRefPubMedGoogle Scholar
  8. 8.
    Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med. 2013;13(1):7–12.CrossRefGoogle Scholar
  9. 9.
    Faith J, Thorburn S, Tippens KM. Examining the association between patient-centered communication and provider avoidance, CAM use, and CAM-use disclosure. Altern Ther Health Med. 2015;21(2):30–5.PubMedGoogle Scholar
  10. 10.
    Ventola CL. Current issues regarding complementary and alternative medicine (CAM) in the United States: Part 1: the widespread use of CAM and the need for better-informed health care professionals to provide patient counseling. P & T Peer Rev J Formul Manag. 2010;35(8):461–8.Google Scholar
  11. 11.
    Shaw D, Graeme L, Pierre D, Elizabeth W, Kelvin C. Pharmacovigilance of herbal medicine. J Ethnopharmacol. 2012;140(3):513–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Jacobsson I, Jonsson AK, Gerden B, Hagg S. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden. Pharmacoepidemiol Drug Saf. 2009;18(11):1039–47.CrossRefPubMedGoogle Scholar
  13. 13.
    Menniti-Ippolito F, Mazzanti G, Santuccio C, Moro PA, Calapai G, Firenzuoli F, et al. Surveillance of suspected adverse reactions to natural health products in Italy. Pharmacoepidemiol Drug Saf. 2008;17(6):626–35.CrossRefPubMedGoogle Scholar
  14. 14.
    WHO Uppsala Monitoring Centre. [cited 2015]. http://www.who-umc.org. Accessed 20 Feb 2016.
  15. 15.
    WHO Uppsala Monitoring Centre. The use of the WHO-UMC system for standardised case causality assessment. [cited 2015]. http://www.who-umc.org/Graphics/26649.pdf. Accessed 20 Feb 2016.
  16. 16.
    WHO Uppsala Monitoring Centre. WHO-ART - MedDRA Cross Reference Tool. [cited 2015]. http://www.umc-products.com/DynPage.aspx?id=73560&mn1=1107&mn2=1664&mn3=6045. Accessed 20 Feb 2016.
  17. 17.
    Farah MH, Olsson S, Bate J, Lindquist M, Edwards R, Simmonds MS, et al. Botanical nomenclature in pharmacovigilance and a recommendation for standardisation. Drug Saf. 2006;29(11):1023–9.CrossRefPubMedGoogle Scholar
  18. 18.
    WHO. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems. [cited 2015]. http://apps.who.int/medicinedocs/en/d/Js7148e/. Accessed 20 Feb 2016.
  19. 19.
    Murphy K, Gawchik S, Bernstein D, Andersen J, Pedersen MR. A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma. J Negat Results Biomed. 2013;12:10.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kay AB. An extract of Timothy-grass pollen used as sublingual immunotherapy for summer hay fever. Review. Drugs Today (Barc). 2007;43(12):841–8.CrossRefGoogle Scholar
  21. 21.
    Norén GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57–69.CrossRefPubMedGoogle Scholar
  22. 22.
    Caster O, Juhlin K, Watson S, Norén GN. Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank. Drug Saf. 2014;37(8):617–28.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    de Groot H, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009;64(6):963–4.CrossRefPubMedGoogle Scholar
  24. 24.
    Andrographis paniculata. In: Jellin JM, Gregory PJ, Calvillo A, et al. Natural medicines comprehensive database. Stockton, CA: Therapeutic Research Center. http://www.naturaldatabase.com/. Accessed 15 Oct 2015.
  25. 25.
    Suwankesawong W, Saokaew S, Permsuwan U, Chaiyakunapruk N. Characterization of hypersensitivity reactions reported among Andrographis paniculata users in Thailand using Health Product Vigilance Center (HPVC) database. BMC Complement Altern Med. 2014;14:515.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Bauer C, Oppel T, Rueff F, Przybilla B. Anaphylaxis to viscotoxins of mistletoe (Viscum album) extracts. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2005;94(1):86–9.CrossRefGoogle Scholar
  27. 27.
    Bregnbak D, Menne T, Johansen JD. Airborne contact dermatitis caused by common ivy (Hedera helix L. ssp. helix). Contact Dermat. 2015;72(4):243–4.CrossRefGoogle Scholar
  28. 28.
    de Boer HJ, Hagemann U, Bate J, Meyboom RH. Allergic reactions to medicines derived from Pelargonium species. Drug Saf. 2007;30(8):677–80.CrossRefPubMedGoogle Scholar
  29. 29.
    Munoz X, Culebras M, Cruz MJ, Morell F. Occupational asthma related to aescin inhalation. Ann Allergy Asthma Immunol Off Publ Am Coll Allergy Asthma Immunol. 2006;96(3):494–6.CrossRefGoogle Scholar
  30. 30.
    Ozdemir C, Schneider LA, Hinrichs R, Staib G, Weber L, Weiss JM, et al. Allergic contact dermatitis to common ivy (Hedera helix L.). Hautarzt. 2003;54(10):966–9.CrossRefPubMedGoogle Scholar
  31. 31.
    Schapowal A. Efficacy and safety of Echinaforce(R) in respiratory tract infections. Wien Med Wochenschr. 2013;163(3–4):102–5.CrossRefPubMedGoogle Scholar
  32. 32.
    Warrington R, Dan FS. Drug allergy. Allergy Asthma Clin Immunol. 2011;7(1):10.CrossRefGoogle Scholar
  33. 33.
    Thiessard F, Roux E, Miremont-Salamé G, Fourrier-Réglat A, Haramburu F, Tubert-Bitter P, et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986–2001). Drug Saf. 2005;28(8):731–40.CrossRefPubMedGoogle Scholar
  34. 34.
    Barsky AJ, Peekna HM, Borus JF. Somatic symptom reporting in women and men. J Gen Intern Med. 2001;16(4):266–75.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Alomar MJ. Factors affecting the development of adverse drug reactions (Review article). Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2014;22(2):83–94.Google Scholar
  36. 36.
    Thong BY, Tan TC. Epidemiology and risk factors for drug allergy. Br J Clin Pharmacol. 2011;71(5):684–700.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
  38. 38.
    George M, Topaz M. A systematic review of complementary and alternative medicine for asthma self-management. Nurs Clin N Am. 2013;48(1):53–149.CrossRefGoogle Scholar
  39. 39.
    Ernst E. Complementary therapies for asthma: what patients use. J Asthma. 1998;35(8):667–71.CrossRefPubMedGoogle Scholar
  40. 40.
    Simons FE, Ebisawa M, Sanchez-Borges M, Thong BY, Worm M, Tanno LK, et al. 2015 update of the evidence base: World Allergy Organization anaphylaxis guidelines. World Allergy Organ J. 2015;8(1):32.Google Scholar
  41. 41.
    Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: an updated systematic review. Drugs. 2009;69(13):1777–98.CrossRefPubMedGoogle Scholar
  42. 42.
    Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev Aust Assoc Clin Biochem. 2013;34(1):15–38.Google Scholar
  43. 43.
    Byard RW. A review of the potential forensic significance of traditional herbal medicines. J Forensic Sci. 2010;55(1):89–92.CrossRefPubMedGoogle Scholar
  44. 44.
    Cellini M, Attipoe S, Seales P, Gray R, Ward A, Stephens M, et al. Dietary supplements: physician knowledge and adverse event reporting. Med Sci Sports Exerc. 2013;45(1):23–8.CrossRefPubMedGoogle Scholar
  45. 45.
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006;29(5):385–96.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Jitka Pokladnikova
    • 1
  • Ronald H. B. Meyboom
    • 2
    • 3
  • Ricarda Meincke
    • 1
  • David Niedrig
    • 4
  • Stefan Russmann
    • 4
    • 5
    • 6
  1. 1.Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec KraloveCharles University in PragueHradec KraloveCzech Republic
  2. 2.WHO Collaborating Centre for International Drug Monitoring, Uppsala Monitoring CentreUppsalaSweden
  3. 3.Division of Pharmacoepidemiology and PharmacotherapyUtrecht UniversityUtrechtThe Netherlands
  4. 4.Division of Clinical Pharmacology and ToxicologyUniversity Hospital ZurichZurichSwitzerland
  5. 5.drugsafety.chKüsnachtSwitzerland
  6. 6.Center for Integrative Human Physiology (ZIHP)University of ZurichZurichSwitzerland

Personalised recommendations